Product Description: Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102.
CAS Number: 1792181-33-9
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related